{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibyiax7fvbfcr4iodtzzhpu2awre4vag6avdec55kaas7qggpj7bq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mouzeershwd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie24wvnk2sy3sbug3shchl62xhygm5pcykgrluw3qmdf2hrhf76uy"
    },
    "mimeType": "image/jpeg",
    "size": 87043
  },
  "path": "/2026/06/22/fda-reverses-course-regenxbio-gene-therapy-navsunli-hunter-syndrome/?utm_campaign=rss",
  "publishedAt": "2026-06-22T10:43:36.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "FDA",
    "Gene therapy",
    "Pharmaceuticals",
    "rare disease",
    "STAT+"
  ],
  "textContent": "The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.",
  "title": "STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection",
  "updatedAt": "2026-06-22T10:48:19.000Z"
}